Study reveals moderate effectiveness of Pfizer-BioNTech’s Covid-19 vaccine against Omicron in children aged 5-11
c4c General Assembly
BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
Severity and Outcomes of Dengue in Hospitalized Jamaican Children in 2018–2019 During an Epidemic Surge in the Americas
🇮🇹 Il vaccino Pfizer-BioNTech BNT162b2 (Comirnaty) offre una protezione moderata dalla variante Omicron nei bambini dai 5 agli 11 anni
The D3 trial is open and recruiting fast!
🇬🇧 Study reveals moderate effectiveness of Pfizer Covid-19 vaccine against Omicron in children aged 5-11
SHIELD trial screens first two patients
EMA updates guideline on the treatment of bacterial infections
Seasonal patterns of SARS-CoV-2 transmission in secondary schools: a modelling study
Omicron Neutralizing and Anti-SARS-CoV-2 S-RBD Antibodies in Naïve and Convalescent Populations After Homologous and Heterologous Boosting With an mRNA Vaccine
Preliminary Evidence on Pulmonary Function after Asymptomatic and Mild COVID-19 in Children
